Neurogene Inc. (NGNE)
| Market Cap | 476.17M -2.9% |
| Revenue (ttm) | n/a |
| Net Income | -111.11M |
| EPS | -5.04 |
| Shares Out | 20.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,397 |
| Open | 23.26 |
| Previous Close | 23.25 |
| Day's Range | 22.78 - 24.20 |
| 52-Week Range | 15.93 - 43.66 |
| Beta | 2.09 |
| Analysts | Strong Buy |
| Price Target | 77.88 (+227.3%) |
| Est. Earnings | Nov 12, 2026 |
About NGNE
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The comp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for NGNE stock is "Strong Buy." The 12-month stock price target is $77.88, which is an increase of 227.30% from the latest price.
News
Neurogene initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Neurogene (NGNE) with an Overweight rating and $60 price target The firm cites the potential of NGN-401, a one-time intracerebroventricular gene therapy delivering funct...
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: H.C. Wainwright 28th Annual Global Investment Conference
NGN-401, a gene therapy for Rett syndrome, has shown strong efficacy and safety in early trials, with all patients gaining developmental milestones. The pivotal Embolden trial is underway, with primary data expected in late 2027, and the company is advancing commercialization and platform expansion.
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene price target lowered to $65 from $70 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Neurogene (NGNE) to $65 from $70 and keeps a Buy rating on the shares. The firm cites the company’s recent dilution for…
Neurogene price target raised to $81 from $69 at Guggenheim
Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Neurogene (NGNE) to $81 from $69 and keeps a Buy rating on the shares. The longer term Phase 1/2 data…
Neurogene price target lowered to $166 from $180 at Canaccord
Canaccord lowered the firm’s price target on Neurogene (NGNE) to $166 from $180 and keeps a Buy rating on the shares. The firm said its 2Q26 report was relatively uneventful…
Neurogene Slides: Corporate presentation
Neurogene has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Neurogene reports Q2 EPS ($1.53), consensus ($1.38)
“The second quarter and recent months marked important progress across our NGN-401 program, highlighted by positive long-term Phase 1/2 data showing durable, multidomain developmental gains that have ...
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Earnings release: Q2 2026
Neurogene released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Neurogene Quarterly report: Q2 2026
Neurogene has published its Q2 2026 quarterly earnings report on August 11, 2026.
Neurogene prices 3.5M shares at $30.00 in public offering
Neurogene (NGNE) announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offering price per share of $30.00 and, in lieu…
Neurogene Inc. Announces Pricing of $125 Million Public Offering
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene 75M Spot Secondary; re-offered at $30.00
Leerink, Stifel, Guggenheim, LifeSci Capital and William Blair are acting as joint book running managers for the offering.
Neurogene announces common stock offering, no amount given
Neurogene (NGNE) announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants…
Neurogene Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: Study result
NGN-401 gene therapy for Rett syndrome showed 100% of phase I/II participants gained developmental milestones, with rapid, durable, and multi-domain improvements sustained up to 30 months. The therapy was well tolerated, exceeded efficacy thresholds, and is on track for regulatory submission and commercialization.
Neurogene Press release: Study result
Neurogene issued a press release on June 29, 2026, disclosing material business information to investors.
Neurogene Slides: Study result
Neurogene has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Neurogene announces data from Phase 1/2 trial of NGN-401
Neurogene (NGNE) announced updated, positive data from its Phase 1/2 clinical trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. Across 10 participants, 47 total de...
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene completes dosing in Embolden trial of NGN-401
Neurogene (NGNE) announced the successful completion of dosing in the Embolden registrational trial of NGN-401. While the initial enrollment target was 20 participants, the statistical analysis plan p...
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: AGM 2026
The meeting confirmed a quorum, elected two directors, approved executive compensation, ratified auditors, and set annual advisory votes on compensation. No shareholder proposals or questions were submitted.